Synergy between an antibody and CD8+ cells in eliminating an established tumor

Ljiljana V. Vasović, Ruben Dyall, Raphael A. Clynes, Jeffrey V. Ravetch, Janko Nikolich-Zugich

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

We investigated the effector mechanisms operating during the rejection of a transplantable solid lymphoma E.G7 (H-2b) which expresses the gene encoding chicken ovalbumin (OVA). Anti-OVA cytotoxic T lymphocytes (CTL) completely and specifically protected animals from the onset of, but could not eradicate established, E.G7 tumors. The growth of the same lymphoma was also effectively prevented by the antibody GK1.5, whose target molecule, CD4, was expressed on E.G7 cells in vivo. Furthermore, GK1.5 was able to eradicate established solid E.G7 tumors. GK1.5-mediated tumor elimination was due to its antitumor activity, and not to the elimination of regulatory CD4+ cells, based on unimpaired tumor growth in the absence of GK1.5 in animals that genetically lack CD4 T cells. In vitro, GK1.5 did not kill tumor cells: complement activation or apoptosis induction were not evident. In vivo, GK1.5-mediated tumor regression did not depend on natural killer cells, but it absolutely required CD8+ cells and intact Fcγ receptor. We conclude that, in the E.G7 model, the collaboration of antibody and CTL immunity was crucial for the successful immunotherapy of established tumors. The mechanism of this collaboration is discussed.

Original languageEnglish (US)
Pages (from-to)374-382
Number of pages9
JournalEuropean Journal of Immunology
Volume27
Issue number2
DOIs
StatePublished - 1997
Externally publishedYes

Fingerprint

Antibodies
Neoplasms
Ovalbumin
Cytotoxic T-Lymphocytes
Lymphoma
CD4 Antigens
Fc Receptors
Complement Activation
Growth
Natural Killer Cells
Immunotherapy
Chickens
Immunity
Apoptosis
T-Lymphocytes
Genes

Keywords

  • Antibody
  • Cytotoxic T lymphocyte
  • Lymphoma
  • Tumor regression

ASJC Scopus subject areas

  • Immunology

Cite this

Synergy between an antibody and CD8+ cells in eliminating an established tumor. / Vasović, Ljiljana V.; Dyall, Ruben; Clynes, Raphael A.; Ravetch, Jeffrey V.; Nikolich-Zugich, Janko.

In: European Journal of Immunology, Vol. 27, No. 2, 1997, p. 374-382.

Research output: Contribution to journalArticle

Vasović, Ljiljana V. ; Dyall, Ruben ; Clynes, Raphael A. ; Ravetch, Jeffrey V. ; Nikolich-Zugich, Janko. / Synergy between an antibody and CD8+ cells in eliminating an established tumor. In: European Journal of Immunology. 1997 ; Vol. 27, No. 2. pp. 374-382.
@article{a11551988dd644879a595f0d1197d827,
title = "Synergy between an antibody and CD8+ cells in eliminating an established tumor",
abstract = "We investigated the effector mechanisms operating during the rejection of a transplantable solid lymphoma E.G7 (H-2b) which expresses the gene encoding chicken ovalbumin (OVA). Anti-OVA cytotoxic T lymphocytes (CTL) completely and specifically protected animals from the onset of, but could not eradicate established, E.G7 tumors. The growth of the same lymphoma was also effectively prevented by the antibody GK1.5, whose target molecule, CD4, was expressed on E.G7 cells in vivo. Furthermore, GK1.5 was able to eradicate established solid E.G7 tumors. GK1.5-mediated tumor elimination was due to its antitumor activity, and not to the elimination of regulatory CD4+ cells, based on unimpaired tumor growth in the absence of GK1.5 in animals that genetically lack CD4 T cells. In vitro, GK1.5 did not kill tumor cells: complement activation or apoptosis induction were not evident. In vivo, GK1.5-mediated tumor regression did not depend on natural killer cells, but it absolutely required CD8+ cells and intact Fcγ receptor. We conclude that, in the E.G7 model, the collaboration of antibody and CTL immunity was crucial for the successful immunotherapy of established tumors. The mechanism of this collaboration is discussed.",
keywords = "Antibody, Cytotoxic T lymphocyte, Lymphoma, Tumor regression",
author = "Vasović, {Ljiljana V.} and Ruben Dyall and Clynes, {Raphael A.} and Ravetch, {Jeffrey V.} and Janko Nikolich-Zugich",
year = "1997",
doi = "10.1002/eji.1830270206",
language = "English (US)",
volume = "27",
pages = "374--382",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "2",

}

TY - JOUR

T1 - Synergy between an antibody and CD8+ cells in eliminating an established tumor

AU - Vasović, Ljiljana V.

AU - Dyall, Ruben

AU - Clynes, Raphael A.

AU - Ravetch, Jeffrey V.

AU - Nikolich-Zugich, Janko

PY - 1997

Y1 - 1997

N2 - We investigated the effector mechanisms operating during the rejection of a transplantable solid lymphoma E.G7 (H-2b) which expresses the gene encoding chicken ovalbumin (OVA). Anti-OVA cytotoxic T lymphocytes (CTL) completely and specifically protected animals from the onset of, but could not eradicate established, E.G7 tumors. The growth of the same lymphoma was also effectively prevented by the antibody GK1.5, whose target molecule, CD4, was expressed on E.G7 cells in vivo. Furthermore, GK1.5 was able to eradicate established solid E.G7 tumors. GK1.5-mediated tumor elimination was due to its antitumor activity, and not to the elimination of regulatory CD4+ cells, based on unimpaired tumor growth in the absence of GK1.5 in animals that genetically lack CD4 T cells. In vitro, GK1.5 did not kill tumor cells: complement activation or apoptosis induction were not evident. In vivo, GK1.5-mediated tumor regression did not depend on natural killer cells, but it absolutely required CD8+ cells and intact Fcγ receptor. We conclude that, in the E.G7 model, the collaboration of antibody and CTL immunity was crucial for the successful immunotherapy of established tumors. The mechanism of this collaboration is discussed.

AB - We investigated the effector mechanisms operating during the rejection of a transplantable solid lymphoma E.G7 (H-2b) which expresses the gene encoding chicken ovalbumin (OVA). Anti-OVA cytotoxic T lymphocytes (CTL) completely and specifically protected animals from the onset of, but could not eradicate established, E.G7 tumors. The growth of the same lymphoma was also effectively prevented by the antibody GK1.5, whose target molecule, CD4, was expressed on E.G7 cells in vivo. Furthermore, GK1.5 was able to eradicate established solid E.G7 tumors. GK1.5-mediated tumor elimination was due to its antitumor activity, and not to the elimination of regulatory CD4+ cells, based on unimpaired tumor growth in the absence of GK1.5 in animals that genetically lack CD4 T cells. In vitro, GK1.5 did not kill tumor cells: complement activation or apoptosis induction were not evident. In vivo, GK1.5-mediated tumor regression did not depend on natural killer cells, but it absolutely required CD8+ cells and intact Fcγ receptor. We conclude that, in the E.G7 model, the collaboration of antibody and CTL immunity was crucial for the successful immunotherapy of established tumors. The mechanism of this collaboration is discussed.

KW - Antibody

KW - Cytotoxic T lymphocyte

KW - Lymphoma

KW - Tumor regression

UR - http://www.scopus.com/inward/record.url?scp=0031045256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031045256&partnerID=8YFLogxK

U2 - 10.1002/eji.1830270206

DO - 10.1002/eji.1830270206

M3 - Article

C2 - 9045907

AN - SCOPUS:0031045256

VL - 27

SP - 374

EP - 382

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 2

ER -